scholarly journals Use of viral load to improve survey estimates of known HIV-positive status and antiretroviral treatment coverage

AIDS ◽  
2020 ◽  
Vol 34 (4) ◽  
pp. 631-636
Author(s):  
Peter W. Young ◽  
Emily Zielinski-Gutierrez ◽  
Joyce Wamicwe ◽  
Irene Mukui ◽  
Andrea A. Kim ◽  
...  
2019 ◽  
Author(s):  
Peter W. Young ◽  
Emily Zielinski-Gutierrez ◽  
Joyce Wamicwe ◽  
Irene Mukui ◽  
Andrea A. Kim ◽  
...  

AbstractObjectiveTo compare alternative methods of adjusting self-reported knowledge of HIV-positive status and antiretroviral (ARV) therapy use based on undetectable viral load (UVL) and ARV detection in blood.DesignPost hoc analysis of nationally-representative household survey to compare alternative biomarker-based adjustments to population HIV indicators.MethodsWe reclassified HIV-positive participants aged 15–64 years in the 2012 Kenya AIDS Indicator Survey (KAIS) that were unaware of their HIV-positive status by self-report as aware and on antiretroviral treatment if either ARVs were detected or viral load was undetectable (<550 copies/mL) on dried blood spots. We compared self-report to adjustments for ARVs measurement, UVL, or both.ResultsTreatment coverage among all HIV-positive respondents increased from 31.8% for self-report to 42.5% [95% confidence interval (CI) 37.4–47.8] based on ARV detection alone, to 42.8% (95% CI 37.9–47.8) when ARV-adjusted, 46.2% (95% CI 41.3–51.1) when UVL-adjusted and 48.8% (95% CI 43.9–53.8) when adjusted for either ARV or UVL. Awareness of positive status increased from 46.9% for self-report to 56.2% (95% CI 50.7– 61.6) when ARV-adjusted, 57.5% (95% CI 51.9–63.0) when UVL-adjusted, and 59.8% (95% CI 54.2–65.1) when adjusted for either ARV or UVL.ConclusionsUndetectable viral load, which is routinely measured in surveys, may be a useful adjunct or alternative to ARV detection for adjusting survey estimates of knowledge of HIV status and antiretroviral treatment coverage.


2015 ◽  
Vol 96 (2) ◽  
pp. 182-186 ◽  
Author(s):  
A A Shteyman ◽  
M B Okhapkin ◽  
Yu V Ershova

Aim. To outline the risk factors for preterm delivery in HIV-positive women.Methods. Clinical histories of 146 pregnancies with a confirmed diagnosis of HIV infection were analyzed. All patients were allocated to 2 groups. The first group included 60 patients who had a preterm delivery prior to 37th week of pregnancy. The second group included 86 patients who delivered at term. To identify the risk factors for preterm delivery, odds ratios were calculated.Results. Risk factors for preterm birth include: infection duration less than 1 year (OR=2.6, 95% CI=1.04-6.49); 4A stage of HIV infection (OR=2.67, 95% CI=1.08-6.60); antiretroviral treatment started on 28th week of pregnancy (OR=5.12, 95% CI=2.37-11.02); oligohydramnios according to the results of second scheduled ultrasonography at 21-22th week of pregnancy (OR=29.0, 95% CI=3.73-158.8) and data for intrauterine growth restriction according to the results of third scheduled ultrasonography at 21-22th week of pregnancy (OR=16.84, 95% CI=5.46-51.93). CD4 count (OR=0.42, 95% CI=0.16-1.02) and viral load (OR=0.43, 95% CI=0.17-1.03) are indicators of patient’s immune status, but do not allow predict the risk of preterm birth.Conclusion. Factors that might be considered as preterm delivery predictors are outlined. Introducing the package of measures aimed at early treatment of HIV-positive pregnant women with the risk factors would allow to reduce the number of preterm deliveries in such patients.


Sexual Health ◽  
2015 ◽  
Vol 12 (5) ◽  
pp. 453 ◽  
Author(s):  
Nicole L. De La Mata ◽  
Limin Mao ◽  
John De Wit ◽  
Don Smith ◽  
Martin Holt ◽  
...  

Gay and other men who have sex with men (GMSM) are disproportionally affected by the HIV epidemic in Australia. The study objective is to combine a clinical-based cohort with a community-based surveillance system to present a broader representation of the GMSM community to determine estimates of proportions receiving antiretroviral therapy (ART) and/or with an undetectable viral load. Between 2010 and 2012, small increases were shown in ART uptake (to 70.2%) and proportions with undetectable viral load (to 62.4%). The study findings highlight the potential for significantly increasing ART uptake among HIV-positive GMSM to reduce the HIV epidemic in Australia.


Author(s):  
Jenita Chiba ◽  
Jeanette Schmid

The lifespan of perinatally HIV-infected children in South Africa has increased owing to the availability of antiretroviral treatment, allowing growth into adolescence and beyond. There is limited knowledge of the lived realities of adolescents with HIV. This paper, using life story methodology and based on Blessing’s narrative, provides an intersectional, complex view of the experience of one such teenager who is perinatally HIV-positive, was abandoned by his family and is living in a residential care facility. His story powerfully illuminates the specific construction of adolescence in this context, focusing on identity formation and the need for connection. The narrative also points to service providers’ practice when engaged with such youths.


2021 ◽  
Vol 14 (6) ◽  
pp. e242633
Author(s):  
Antonio Jose Reyes ◽  
Kanterpersad Ramcharan ◽  
Samuel Aboh ◽  
Stanley Lawrence Giddings

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Rita Nakalega ◽  
Nelson Mukiza ◽  
Henry Debem ◽  
George Kiwanuka ◽  
Ronald Makanga Kakumba ◽  
...  

Abstract Background Antiretroviral therapy (ART) adherence is a primary determinant of sustained viral suppression, HIV transmission risk, disease progression and death. The World Health Organization recommends that adherence support interventions be provided to people on ART, but implementation is suboptimal. We evaluated linkage to intensive adherence counselling (IAC) for persons on ART with detectable viral load (VL). Methods Between January and December 2017, we conducted a retrospective chart review of HIV-positive persons on ART with detectable VL (> 1000 copies/ml), in Gomba district, rural Uganda. We abstracted records from eight HIV clinics; seven health center III’s (facilities which provide basic preventive and curative care and are headed by clinical officers) and a health center IV (mini-hospital headed by a medical doctor). Linkage to IAC was defined as provision of IAC to ART clients with detectable VL within three months of receipt of results at the health facility. Descriptive statistics and multivariable logistic regression analyses were used to evaluate factors associated with linkage to IAC. Results Of 4,100 HIV-positive persons on ART for at least 6 months, 411 (10%) had detectable VL. The median age was 32 years (interquartile range [IQR] 13–43) and 52% were female. The median duration on ART was 3.2 years (IQR 1.8–4.8). A total of 311 ART clients (81%) were linked to IAC. Receipt of ART at a Health Center level IV was associated with a two-fold higher odds of IAC linkage compared with Health Center level III (adjusted odds ratio [aOR] 1.78; 95% CI 1.00–3.16; p = 0.01). Age, gender, marital status and ART duration were not related to IAC linkage. Conclusions Linkage to IAC was high among persons with detectable VL in rural Uganda, with greater odds of linkage at a higher-level health facility. Strategies to optimize IAC linkage at lower-level health facilities for persons with suboptimal ART adherence are needed.


2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Anita Mesic ◽  
Alexander Spina ◽  
Htay Thet Mar ◽  
Phone Thit ◽  
Tom Decroo ◽  
...  

Abstract Background Progress toward the global target for 95% virological suppression among those on antiretroviral treatment (ART) is still suboptimal. We describe the viral load (VL) cascade, the incidence of virological failure and associated risk factors among people living with HIV receiving first-line ART in an HIV cohort in Myanmar treated by the Médecins Sans Frontières in collaboration with the Ministry of Health and Sports Myanmar. Methods We conducted a retrospective cohort study, including adult patients with at least one HIV viral load test result and having received of at least 6 months’ standard first-line ART. The incidence rate of virological failure (HIV viral load ≥ 1000 copies/mL) was calculated. Multivariable Cox’s regression was performed to identify risk factors for virological failure. Results We included 25,260 patients with a median age of 33.1 years (interquartile range, IQR 28.0–39.1) and a median observation time of 5.4 years (IQR 3.7–7.9). Virological failure was documented in 3,579 (14.2%) participants, resulting in an overall incidence rate for failure of 2.5 per 100 person-years of follow-up. Among those who had a follow-up viral load result, 1,258 (57.1%) had confirmed virological failure, of which 836 (66.5%) were switched to second-line treatment. An increased hazard for failure was associated with age ≤ 19 years (adjusted hazard ratio, aHR 1.51; 95% confidence intervals, CI 1.20–1.89; p < 0.001), baseline tuberculosis (aHR 1.39; 95% CI 1.14–1.49; p < 0.001), a history of low-level viremia (aHR 1.60; 95% CI 1.42–1.81; p < 0.001), or a history of loss-to-follow-up (aHR 1.24; 95% CI 1.41–1.52; p = 0.041) and being on the same regimen (aHR 1.37; 95% CI 1.07–1.76; p < 0.001). Cumulative appointment delay was not significantly associated with failure after controlling for covariates. Conclusions VL monitoring is an important tool to improve programme outcomes, however limited coverage of VL testing and acting on test results hampers its full potential. In our cohort children and adolescents, PLHIV with history of loss-to-follow-up or those with low-viremia are at the highest risk of virological failure and might require more frequent virological monitoring than is currently recommended.


Sign in / Sign up

Export Citation Format

Share Document